CC
IONS icon

Casdin Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Casdin Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-33,000
Closed -$1.21M – 28
2016
Q3 		$1.21M Buy
+33,000
New +$1.03M 0.98% 24

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital's IONS Position: Q4 2016 in Review

Casdin Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2016, closing a stake of 33,000 shares — an estimated $1.21M sold.

Casdin Capital first reported a position in IONS in Q3 2016 and held it in 1 quarter. The position peaked at $1.21M in Q3 2016. 308 funds tracked by Wall St. Rank hold IONS as of Q4 2016.

  • Casdin Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Casdin Capital sold 33,000 Ionis Pharmaceuticals shares in Q4 2016, an estimated $1.21M.
  • Casdin Capital first reported a position in Ionis Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Casdin Capital's Ionis Pharmaceuticals position peaked at $1.21M in Q3 2016.
  • 308 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2016.

Based on Casdin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.